FLNA in HCC Patients

University of Milan

Status: Completed

Conditions: Hepatocellular Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT03081637

FLNA in HCC

Details and patient eligibility

About

The risk of recurrence after hepatectomy for hepatocellular carcinoma (HCC) is very high. Having a predictive marker of early recurrence (ER) would be desirable to personalize the follow-up and possibly develop new targeted therapy. The aim of this study was to test the expression of Filamin A (FLNA) in a cohort of patients operated for HCC.

Full description

A consecutive cohort of resected HCC patients will be analyzed. Several different prognostic factors, including FLNA expression, will be tested against the risk of ER. FLNA expression will be analyzed with immunohistochemistry in the intra-tumoral and extra-tumoral tissue compartments using a dedicated tissue microarray.

Enrollment: 115 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The inclusion criteria were represented by the histological positivity for HCC with complete clinical, surgical, pathological, and follow-up data.

Exclusion criteria

• Patients preoperatively treated with chemotherapy or trans-arterial therapy were excluded.
• Similarly, patients operated for recurrent HCC or with non-radical surgery or with missing data were excluded.